Evidence map›Paper›PMID 33992933›Full record

ArticleEpilepsy & behavior : E&B2021

Influence of COVID-19 pandemic on quality of life in patients with epilepsy - Follow-up study.

Selena Strizović, Nikola Vojvodić, Maša Kovačević, Aleksa Pejović, Zoran Bukumirić, Dragoslav Sokić, Aleksandar J Ristić

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epilepsy & behavior : E&B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Selena StrizovićFaculty of Medicine, University of Belgrade, Serbia.
Nikola VojvodićClinic for Neurology, University Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbia.
Maša KovačevićClinic for Neurology, University Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbia.
Aleksa PejovićClinic for Neurology, University Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbia.
Zoran BukumirićMedical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Serbia.
Dragoslav SokićClinic for Neurology, University Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbia.
Aleksandar J RistićClinic for Neurology, University Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbia. Electronic address: aristic@eunet.rs.
University of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo perform a follow-up study of the quality of life in patients with epilepsy in the era of the COVID-19 crisis.

methodsTwo months before the first case of the COVID-19 in Serbia, we obtained the Serbian Version of Quality of Life Inventory for Epilepsy 31 (SVQOLIE-31) and Neurological Disorders Depression Inventory for Epilepsy scores (SVNDDI-E) for another study. We retested the same patients one year after in COVID-19 pandemic. In addition to SVQOLIE-31, and SVNDDI-E we used a generic questionnaire compiled from items related to the COVID-19.

resultsWe retested 97 out of 118 patients (82.2%) for the follow-up analysis. The average age was 36.1 ± 12.2 (range: 18-69), and 49 were women (50.5%). The median duration of epilepsy was 13 years (range: 1.5-48). The structural etiology of epilepsy was noted in 41 (42.3%), unknown etiology in 41 (42.3%), and genetic etiology in 15 (15.4%) patients. Fewer patients (27.8%) experienced at least one seizure three months before follow-up testing when compared to patients who experienced at least one seizure three months in initial testing (36.0%) (p = 0.15). All patients reported full compliance with anti-seizure medication in the follow-up. The SVQOLIE-31 score during the COVID-19 pandemic visit (64.5 ± 14.6) was significantly lower than the SVQOLIE-31 score before the pandemic (p < 0.001). The SVNDDI-E score during the COVID-19 pandemic (10.5 ± 3.5) was significantly higher than the SVNDDI-E score before it (p < 0.001). Multiple linear regression analyses revealed fear of seizures, and fear of a reduction in household income, significantly associated with SVQOLIE-31 and SVNDDI-E overall score. These variables accounted for 66% and 27% of the variance of SVQOLIE-31 and SVNDDI-E overall score. SIGNIFICANCE: Lower quality of life, higher prevalence of depression, healthcare availability issues, and perceived fears during pandemic all suggest COVID-19 has negatively impacted lives of patients with epilepsy.

Indexed as

COVID-19EpilepsyAdultFemaleFollow-Up StudiesHumansMiddle AgedPandemicsQuality of LifeSARS-CoV-2SerbiaSurveys and QuestionnairesYoung AdultDepressionEpilepsy, COVID-19NDDI-EQOLIE-31Quality of life

Identifiers

PMID33992933
PMCPMC8098040
OpenAlexW3159668960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.